News Page

AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS)
Subscribe to the AIDSinfo At-a-Glance
e-newsletter to receive regular updates on the latest in HIV/AIDS treatment, prevention, and research.
  • NIH-Led Scientists Discover HIV Antibody that Binds to Novel Target on Virus
    "An NIH-led team of scientists has discovered a new vulnerability in the armor of HIV that a vaccine, other preventive regimen or treatment could exploit. The site straddles two proteins, gp41 and gp120, that jut out of the virus and augments other known places where broadly neutralizing antibodies (bNAbs) bind to HIV. This newly identified site on the viral spike is where a new antibody found by the scientists in an HIV-infected person binds to the virus. Called 35O22, the antibody prevents 62 percent of known HIV strains from infecting cells in the laboratory and is extremely potent, meaning even a relatively small amount of it can neutralize the virus."

    More information is available:
  • AIDSinfo Glossary App Updated for iOS 7
    The free AIDSinfo HIV/AIDS Glossary apps for Apple and Android devices provide on-the-go access to definitions for more than 700 HIV/AIDS-related terms in English and Spanish. The apps also include an audio feature so users can hear the correct pronunciation of each term.
     
    The Glossary app for iPhone, iPad, and iPod touch is now optimized for iOS7. The updated app features an iOS7-compatible look and feel and a new icon. The upgrade also included minor bug fixes.
     
    Whether you are new to the Glossary app or a long-time user, download the latest, iOS7-optimized version of the app for your Apple device today. Feedback on the updated app is welcome. Please e-mail your comments to ContactUs@aidsinfo.nih.gov.
     
  • CDC Seeks Public Comments on Newly Developed Draft Clinical Quality Measure for HIV Screening
    The Centers for Disease Control and Prevention (CDC) is seeking public comments on a newly developed draft clinical quality measure for HIV infection screening. The measure aligns with the U.S. Preventive Services Task Force (USPSTF) recommendations that all individuals between the ages of 15 and 65 be screened for HIV. The measure was developed in collaboration with clinicians and quality experts. The goal is to develop a measure that will be nationally endorsed through the National Quality Forum (NQF) and included in the Centers for Medicare and Medicaid Services (CMS) programs.

    Public comments will be accepted through October 20, 2014. For information on how to submit comments, please view the public notice on the CMS website.
  • FDA Updates Etravirine Labeling
    "On August 20, 2014, the Intelence (etravirine) label was updated to include information regarding coadministration of etravirine with the following drugs:
    • "dolutegravir, dolutegravir/darunavir/ritonavir, dolutegravir/lopinavir/ritonavir
    • "atazanavir/ritonavir
    • "boceprevir"
    The updated labeling for etravirine is available at the FDA website.

    More information is available:
  • CDC Launches HIV Treatment Works Campaign
    CDC recently launched HIV Treatment Works, a new national campaign focused on encouraging people infected with HIV to get into care and adhere to treatment. The website includes information and resources for people living with HIV, including information on treatment adherence and tips for healthy living. Visit the HIV Treatment Works website to find an HIV care provider, an HIV support group, or mental health provider.

    For more information, view the CDC press release
  • FDA Approves Two Medications to Treat HIV Infection: Cobicistat (Brand Name: Tybost) and Elvitegravir (Brand Name: Vitekta)
    "On September 24, 2014, FDA approved Tybost (cobicistat) 150 mg tablets. Tybost is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection."

    For more information on cobicistat, view the FDA press release.

    "On September 24, 2014, FDA approved Vitekta (elvitegravir) 85 mg and 150 mg tablets. Vitekta is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor indicated in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults."

    For more information on elvitegravir, view the FDA press release.

    The labeling for both drugs will be available soon at the FDA website